Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort

Portal et al. (Tue,) studied this question.

www.synapsesocial.com/papers/69dd398e7808b00a4799b86e — DOI: https://doi.org/10.1038/bjc.2015.328

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: Report of an effective new strategy· 2014 · 20 citations
2. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group· 2011 · 380 citations
3. PANCREOX: A randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)-based chemotherapy (CT).· 2014 · 49 citations
4. Cancer statistics, 2012· 2012 · 10,711 citations
5. Pancreatic Cancer· 2010 · 2,564 citations